Literature DB >> 15723046

Directed evolution of human T-cell receptors with picomolar affinities by phage display.

Yi Li, Ruth Moysey, Peter E Molloy, Anne-Lise Vuidepot, Tara Mahon, Emma Baston, Steven Dunn, Nathaniel Liddy, Jansen Jacob, Bent K Jakobsen, Jonathan M Boulter.   

Abstract

Peptides derived from almost all proteins, including disease-associated proteins, can be presented on the cell surface as peptide-human leukocyte antigen (pHLA) complexes. T cells specifically recognize pHLA with their clonally rearranged T-cell receptors (TCRs), whose natural affinities are limited to approximately 1-100 muM. Here we describe the display of ten different human TCRs on the surface of bacteriophage, stabilized by a nonnative interchain disulfide bond. We report the directed evolution of high-affinity TCRs specific for two different pHLAs: the human T-cell lymphotropic virus type 1 (HTLV-1) tax(11-19) peptide-HLA-A(*)0201 complex and the NY-ESO-1(157-165) tumor-associated peptide antigen-HLA-A(*)0201 complex, with affinities of up to 2.5 nM and 26 pM, respectively, and we demonstrate their high specificity and sensitivity for targeting of cell-surface pHLAs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723046     DOI: 10.1038/nbt1070

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  203 in total

1.  TCR affinity and specificity requirements for human regulatory T-cell function.

Authors:  Gabriela Plesa; Lingjie Zheng; Andrew Medvec; Caleph B Wilson; Camila Robles-Oteiza; Nathaniel Liddy; Alan D Bennett; Jessie Gavarret; Annelise Vuidepot; Yangbing Zhao; Bruce R Blazar; Bent K Jakobsen; James L Riley
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  The structure of superantigen complexed with TCR and MHC reveals novel insights into superantigenic T cell activation.

Authors:  Maria Saline; Karin E J Rödström; Gerhard Fischer; Vladislav Yu Orekhov; B Göran Karlsson; Karin Lindkvist-Petersson
Journal:  Nat Commun       Date:  2010-11-16       Impact factor: 14.919

3.  Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors.

Authors:  David H Aggen; Adam S Chervin; Francis K Insaidoo; Kurt H Piepenbrink; Brian M Baker; David M Kranz
Journal:  Protein Eng Des Sel       Date:  2010-12-14       Impact factor: 1.650

4.  Fine-tuning of T-cell receptor avidity to increase HIV epitope variant recognition by cytotoxic T lymphocytes.

Authors:  Michael S Bennett; Aviva Joseph; Hwee L Ng; Harris Goldstein; Otto O Yang
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

Review 5.  T cell engineering as therapy for cancer and HIV: our synthetic future.

Authors:  Carl H June; Bruce L Levine
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

Review 6.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors:  X Wang; I Rivière
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

7.  Functional TCR T cell screening using single-cell droplet microfluidics.

Authors:  Aude I Segaliny; Guideng Li; Lingshun Kong; Ci Ren; Xiaoming Chen; Jessica K Wang; David Baltimore; Guikai Wu; Weian Zhao
Journal:  Lab Chip       Date:  2018-12-04       Impact factor: 6.799

Review 8.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

10.  Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity.

Authors:  Akshata Udyavar; Rajshekhar Alli; Phuong Nguyen; Lesley Baker; Terrence L Geiger
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.